Endogenous estrogen signaling pathway may be locally escalated by the elevated estrogen production from the ovary and/or the tumor microenvironment, or via mutations of estrogen receptors, a process that can switch from proinflammation to anti-inflammation, as discussed in Section 3.3. This evidence concerns the gene ESR1 and neoplasm.